Drug Trial Radar · NCT06635850
A Study of Mosliciguat in PH-ILD
Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
135
Actual
Start
Oct 29, 2024
Primary completion
May 26, 2026
Study completion Jan 2028
Sponsor
- Lead sponsor
- Pulmovant, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Conditions
- Pulmonary Hypertension
- Interstitial Lung Disease
- Lung Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Fibrosis
Interventions
MosliciguatDrug
Dose level 1, 2, or 3 for inhalation
Dry Powder InhalerDevice
Dry powder inhaler for mosliciguat or placebo delivery
PlaceboDrug
Matching placebo for inhalation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline to Week 16 in Pulmonary Vascular Resistance (PVR)Time frame: Baseline, Week 16
Locations
85 sites in 20 countries. Site status is shown where the registry gives one.
Clinical Research Site
Phoenix, Arizona
Clinical Research Site
Los Angeles, California
Clinical Research Site
Sacramento, California
Clinical Research Site
Santa Barbara, California
Clinical Research Site
Torrance, California
Clinical Research Site
Washington D.C., District of Columbia
Clinical Research Site
Celebration, Florida
Clinical Research Site
Chicago, Illinois
Clinical Research Site
Iowa City, Iowa
Clinical Research Site
Kansas City, Kansas
Clinical Research Site
Louisville, Kentucky
Clinical Research Site
Boston, Massachusetts
Clinical Research Site
Boston, Massachusetts
Clinical Research Site
New York, New York
Clinical Research Site
New York, New York
Clinical Research Site
Durham, North Carolina
Clinical Research Site
Greensboro, North Carolina
Clinical Research Site
Cincinnati, Ohio
Clinical Research Site
Bend, Oregon
Clinical Research Site
Philadelphia, Pennsylvania
Clinical Research Site
East Providence, Rhode Island
Clinical Research Site
Charleston, South Carolina
Clinical Research Site
Dallas, Texas
Clinical Research Site
Houston, Texas
Clinical Research Site
Salt Lake City, Utah
Clinical Research Site
Santa Fe, Argentina
Clinical Research Site
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Clinical Research Site
Sydney, New South Wales, Australia
Clinical Research Site
Westmead, New South Wales, Australia
Clinical Research Site
Auchenflower, Queensland, Australia
Clinical Research Site
Brussels, Brussels Capital, Belgium
Clinical Research Site
Leuven, Flanders, Belgium
Clinical Research Site
São Paulo, Brazil
Clinical Research Site
São Paulo, Brazil
Clinical Research Site
Porto Alegre, Rio Grande do Sul, Brazil
Clinical Research Site
Blumenau, Santa Catarina, Brazil
Clinical Research Site
Calgary, Alberta, Canada
Clinical Research Site
London, Ontario, Canada
Clinical Research Site
Toronto, Ontario, Canada
Clinical Research Site
Prague, Prague, Czechia
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.